Teva has reached a settlement in its patent battle with two pharmaceutical companies, ending all litigation over its ProAir HFA (albuterol sulfate) inhalation aerosol.
Europe’s highest court has said that products used by agrochemical companies to help maintain plants can be given extended patent protection.
Holland & Knight LLP has expanded its IP practice group with the hire of patent litigator Howard Suh as partner.
Stem cell research companies in Canada and Australia have teamed up to support increased research and development in both countries.
Drug giant Merck is to acquire biopharmaceutical company Idenix for $24.50 per share, valuing the purchase at around $3.85 billion.
Irish-based drug manufacturer Actavis has settled its patent dispute with Zydus Pharmaceuticals.
Law firm Dechert LLP has appointed Rüdiger Herrmann as a partner in its Frankfurt office.
AMAG Pharmaceuticals, Inc. has had a US patent covering ferumoxytol extended.
Kite Pharma, a biotech company, has entered into a licensing agreement with the US’s National Institute of Health that will give it the IP rights to T-cell therapies developed to treat cancer.
Pharmaceutical professionals should have a “wide-ranging” debate on how IP can be tailored in the face of “major changes” to the industry, including the possibility of “prolonged exclusivity” for certain medicines, according to a report.